Nobody can tell you what week 3 will feel like for you. What the Wegovy prescribing information (revised June 2026) and the STEP trials can tell you is how often side effects happened in large groups, and in which phase of treatment they were most common. This page is organized by those phases.
| Reaction | Wegovy 2.4 mg | Placebo | Extra cases per 100 people |
|---|---|---|---|
| Nausea | 44% | 16% | 28 |
| Diarrhea | 30% | 16% | 14 |
| Vomiting | 24% | 6% | 18 |
| Constipation | 24% | 11% | 13 |
| Abdominal pain | 20% | 10% | 10 |
| Headache | 14% | 10% | 4 |
| Fatigue | 11% | 5% | 6 |
| Dyspepsia | 9% | 3% | 6 |
| Dizziness | 8% | 4% | 4 |
| Belching (eructation) | 7% | under 1% | about 6 |
| Hair loss | 3% | 1% | 2 |
The right-hand column is simple subtraction. It shows how many more people per hundred had the reaction on semaglutide than on placebo, which is a fairer read than the headline percentage, since placebo groups report nausea and headaches too.
Phase 1: the escalation weeks (roughly weeks 1–16)
This is where stomach effects concentrate. The label says nausea, vomiting and diarrhea "were most frequently reported during dosage escalation", which on the standard schedule means the four-week steps from 0.25 mg to 1.7 mg. The STEP-1 trial report (NEJM, 2021) describes nausea and diarrhea as typically transient, mild to moderate, and subsiding with time.
Each dose increase can restart the cycle. That is why the label lets your prescriber delay a step, and why a slow climb is not a failure.
- Severity: severe gastrointestinal reactions were reported by 4.1% on Wegovy versus 0.9% on placebo, per the label.
- Stopping: 4.3% of adults on Wegovy stopped permanently because of gastrointestinal reactions, versus 0.7% on placebo. STEP-1 alone reported 4.5% versus 0.8%.
- Heart rate: the label reports mean resting increases of 1 to 4 beats per minute; increases of 20 or more were seen in 26% on Wegovy versus 16% on placebo.
Phase 2: maintenance at 2.4 mg
Side effects do not vanish at maintenance; they become less dominant. STEP-4 (JAMA, 2021) is the best window into this phase. Everyone first took semaglutide for 20 weeks to reach 2.4 mg, and then half switched to placebo. From week 20 to week 68, gastrointestinal events were still reported by 49.1% of those who stayed on semaglutide, versus 26.1% after the switch to placebo. Only 2.4% versus 2.2% stopped treatment because of adverse events in that stretch.
Read that as: stomach complaints remained common, but few people quit over them once past escalation.
Are side effects different for teenagers?
Wegovy injection is also labeled for adolescents 12 and older with obesity, and the label flags one difference. Gallbladder problems were more frequent in pediatric patients than in adults: gallstones in 3.8% of adolescents on Wegovy versus 0% on placebo, and gallbladder inflammation in 0.8% versus 0%. The label also notes that data are too limited to judge the risk of low blood sugar in adolescents with type 2 diabetes.
If you are a parent reading this for a teenager, the escalation phase works the same way, and the same warning signs apply. Ask the prescriber how often they plan to check in during the first 16 weeks.
Phase 3: moving up to 7.2 mg
If your prescriber moves you to Wegovy HD 7.2 mg, expect a second adjustment. In the label's 7.2 mg data, nausea was reported by 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo; vomiting by 22%, 16% and 6%. Dysesthesia, an abnormal skin sensation such as tingling or burning, was reported by 22% on 7.2 mg versus 6% on 2.4 mg. Hair loss was 6% versus 3%.
Any phase: which symptoms need a call?
A few reactions are rare but serious, and they are not tied to a particular week. The label lists these warnings:
- Pancreatitis. Confirmed in 0.2 cases per 100 patient-years on Wegovy versus under 0.1 on placebo. Severe, persistent abdominal pain, sometimes spreading to the back, with or without vomiting, means stop and seek care.
- Gallbladder disease. Gallstones were reported by 1.6% versus 0.7% of adults, and gallbladder inflammation by 0.6% versus 0.2%. Upper-right abdominal pain, fever, yellowing skin or clay-colored stools need evaluation.
- Dehydration and kidney injury. Acute kidney injury occurred at 0.4 versus 0.2 per 100 patient-years, mostly in people who had vomiting, diarrhea or dehydration. If you cannot keep fluids down, call that day.
- Low blood sugar with diabetes drugs. In the type 2 diabetes trial, clinically significant hypoglycemia occurred in 6.2% versus 2.5%. The risk rises with insulin or a sulfonylurea.
- Vision changes with diabetes. Diabetic retinopathy complications were reported by 4% versus 2.7% in that trial.
- Before anesthesia. The label cites rare reports of pulmonary aspiration during general anesthesia or deep sedation. Tell the team doing any procedure that you take semaglutide.
What should you report, and to whom?
Report any of the warning signs above to your prescriber, plus vomiting or diarrhea that lasts more than a day or two, a lump or swelling in the neck, hoarseness or trouble swallowing (the label's thyroid tumor warning symptoms), and a rapid heartbeat at rest.
You can also report side effects to FDA's MedWatch program. FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, says it had received 990 adverse event reports for compounded semaglutide as of May 31, 2026, and notes underreporting is likely. Compounded semaglutide is not FDA-approved, and its side-effect rates were never measured in trials like these.
For the background on how the drug acts in the gut, see how GLP-1 drugs work; for side effects across the class, our GLP-1 side effects guide; and for the trial details behind these numbers, STEP trial results.
Frequently asked questions
When do semaglutide side effects usually start?
The label does not give a start date, but it says gastrointestinal reactions were reported most often during dose escalation, which spans the first 16 weeks on the standard Wegovy schedule. Each dose increase can bring a new round of nausea or fullness. The STEP-1 report describes these effects as usually transient and mild to moderate.
Do semaglutide side effects go away?
For many trial participants they eased, but they did not disappear for everyone. In STEP-4, gastrointestinal events were still reported by 49.1% of people continuing semaglutide between weeks 20 and 68, against 26.1% on placebo. Only 2.4% stopped because of adverse events during that period, so most were manageable.
How many people stop semaglutide because of side effects?
In the Wegovy label's adult weight trials, 4.3% stopped permanently because of gastrointestinal reactions, compared with 0.7% on placebo, and 6.8% stopped for any adverse reaction across three of the trials. STEP-1 alone reported 4.5% stopping for gastrointestinal events. Those figures come from supervised trials with the branded product.
Is hair loss a side effect of semaglutide?
The Wegovy label lists hair loss in 3% of adults on 2.4 mg versus 1% on placebo, and in 6% on the 7.2 mg dose. The label does not say whether it is caused by the drug itself or by rapid weight loss, so ask your prescriber if you notice shedding.
Which semaglutide side effects are an emergency?
Severe abdominal pain that will not ease, especially if it spreads to the back, can signal pancreatitis. Signs of a serious allergic reaction, such as swelling of the face or throat or trouble breathing, need immediate care. Being unable to keep fluids down risks dehydration and kidney injury, which the label links to most kidney cases.
Sources
- FDA label via DailyMed: Wegovy (semaglutide) prescribing information — revised 6/2026; adverse reaction table, warnings, 7.2 mg data read 2026-11-08
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989-1002 — abstract read 2026-11-08 (PubMed record)
- Rubino D et al. Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021;325:1414-1425 — abstract read 2026-11-08 (PubMed record)
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — content current as of 2026-10-01; adverse event counts read 2026-11-08